Elite Pharmaceuticals Reports 92% Revenue Growth in Q2

The latest announcement is out from Elite Pharmaceuticals ( (ELTP) ).

Elite Pharmaceuticals, Inc. reported significant financial growth for the second quarter of fiscal year 2026, ending September 30, 2025, with consolidated revenues reaching $36.3 million, marking a 92% increase from the same period in the previous fiscal year. This growth was largely driven by the successful launch of lisdexamfetamine products and strong performance of the Elite label product lines, resulting in an income from operations of $8.2 million, a 136% increase from the prior year.

The most recent analyst rating on (ELTP) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Elite Pharmaceuticals stock, see the ELTP Stock Forecast page.

Spark’s Take on ELTP Stock

According to Spark, TipRanks’ AI Analyst, ELTP is a Neutral.

The overall stock score is primarily impacted by financial performance and valuation concerns. While revenue growth is strong, profitability issues and cash flow inconsistencies pose significant risks. Technical analysis indicates mixed signals, with no clear trend, and valuation metrics are unattractive due to negative earnings and lack of dividends.

To see Spark’s full report on ELTP stock, click here.

More about Elite Pharmaceuticals

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. The company’s product lines include immediate-release and controlled-release solid oral dose products, marketed under the Elite Laboratories label and through licenses to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility in Northvale, NJ.

Average Trading Volume: 1,208,683

Technical Sentiment Signal: Buy

Current Market Cap: $714.9M

For detailed information about ELTP stock, go to TipRanks’ Stock Analysis page.